Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463154 | 0.93 | PTGDR2 (0.57) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL1997514 | 0.89 | PTGDR2 (0.67) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL1992488 | 0.89 | PTGDR2 (0.53) | PTGDR2NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL1992646 | 0.86 | PTGDR2 (0.53) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL2001901 | 0.86 | NPC1 (0.54) | PTGDR2NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL2467075 | 0.85 | NPSR1 (0.53) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL2002328 | 0.84 | TDP1 (0.50) | PTGDR2NPC1RAB9ATSHRMAPT | |
| SCHEMBL2002169 | 0.84 | PTGDR2 (0.68) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL1993359 | 0.83 | PTGDR2 (0.55) | PTGDR2NPC1RAB9AL3MBTL1TSHR | |
| SCHEMBL2462495 | 0.83 | PTGDR2 (0.47) | PTGDR2NPC1RAB9AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-11-03 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| US-8022063-B2 | CRTH2 receptor ligands for medicinal uses | 7TM PHARMA A/S (DK) | 2011-09-20 | — | — | US | disclosed |
| EP-2336113-A1 | CRTH2 Receptor Ligands for Medical Use | 7TM Pharma A/S (DK) | 2011-06-22 | — | — | EP | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | 7TM PHARMA A/S (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-1758579-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115382-A1 | CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099189-A1 | CRTH2 Receptor Ligands For Medicinal Uses | HRH1, HRH2, HRH3 | PTGDR2 70/4885NPC1 2796/4885RAB9A 2702/4885 |
| US-20110269763-A1 | CRTH2 receptor ligands for medicinal uses | HRH1, HRH2, HRH4 | PTGDR2 61/4885NPC1 2431/4885RAB9A 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.